SP 1x500/25mg + AQ 3x eq.150-153mg base,cobl.disp.tab,9-17kg

STD DORASPAQ2TD2

Valid Article


Article is intended to be used with children (<12 years) ONLY.
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
P01BD51
Anatomical Therapeutic Chemical Classification according to WHOCC
The order of this product needs to be justified and is only acceptable under certain conditions.
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.

OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

https://unicat.msf.org/web/image/product.template/570275/image_1920?unique=00b72e3

This combination does not exist.

Add article to list

   

Add Kit To Wishlist

   

SULFADOXINE/PYRIMETHAMINE (SP) + AMODIAQUINE (AQ)

Therapeutic Action

Co-blister of three antimalarials containing:

Indications

Seasonal malaria chemoprevention in children

Some restricted information has been hidden. Sign in to see this information

Instructions for use

Dispersible tablets intended for paediatric use.

Two different presentations for 2 categories of weight:

  • infants: 2-11 months, 4.5-8 kg
  • children: 1-5 years, 9-17 kg
Infants 2-11 months Children 1-5 years

SP

250/12.5mg

AQ

75-76.5mg

SP

500/25mg

AQ

150-153mg

(DORASPAQ1TD2)(DORASPAQ2TD2)
Day 11 tablet1 tablet1 tablet1 tablet
Day 2-1 tablet-1 tablet
Day 3-1 tablet-1 tablet

Contact your OC malaria advisor to determine the number of courses.

The quantity to be ordered is calculated per blister (= one preventive treatment‌), not per tablet.

Storage

Below 25°C ‐ Protect from sunlight